
Cancer Education · Research
CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026
How to sequence relapsed diffuse large B-cell lymphoma therapy in 2026: CAR-T eligibility, bispecific antibody combinations like SUNMO and STARGLO, bridging strategies, and frontline changes ahead.
By Marin Xavier, MD





























